Scarica l'app Stockscreener
10.90
0.97%
0.105
Precedente Chiudi:
$10.80
Aprire:
$10.83
Volume 24 ore:
370.24K
Relative Volume:
0.39
Capitalizzazione di mercato:
$626.34M
Reddito:
Utile/perdita netta:
$-52.79M
Rapporto P/E:
-14.00
EPS:
-0.7789
Flusso di cassa netto:
$-53.49M
1 W Prestazione:
+5.98%
1M Prestazione:
-20.05%
6M Prestazione:
+16.38%
1 anno Prestazione:
+382.52%
Intervallo 1D:
$10.60
$11.26
Intervallo di 1 settimana:
$9.61
$10.99
Portata 52W:
$1.635
$18.33
Climb Bio Inc Stock (CLYM) Company Profile
Nome
Climb Bio Inc
Settore
Industria
Telefono
1-866-857-2596
Indirizzo
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
10.90 | 626.34M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
525.95 | 133.31B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
251.59 | 100.45B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
805.83 | 82.96B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
889.12 | 55.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
388.46 | 43.94B | 5.76B | 514.49M | 1.10B | 4.4813 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-06-08 | Iniziato | Guggenheim | Buy |
| 2026-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2026-04-15 | Iniziato | Mizuho | Outperform |
| 2026-03-24 | Iniziato | B. Riley Securities | Buy |
| 2026-03-18 | Iniziato | Truist | Buy |
| 2026-03-11 | Iniziato | Raymond James | Strong Buy |
| 2026-03-05 | Iniziato | Wedbush | Outperform |
| 2026-02-13 | Iniziato | Piper Sandler | Overweight |
| 2025-10-16 | Iniziato | William Blair | Outperform |
| 2025-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-08-15 | Iniziato | Robert W. Baird | Outperform |
| 2025-06-06 | Iniziato | Oppenheimer | Outperform |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Climb Bio Inc Borsa (CLYM) Ultime notizie
Climb Bio's Upcoming Data Updates on CLYM116, Budoprutug to Be 'More Incremental,' RBC Says - marketscreener.com
H.C. Wainwright reiterates Climb Bio stock rating ahead of data By Investing.com - Investing.com Canada
Climb Bio, Inc. (CLYM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alpha Cognition Inc. Common Stock (ACOG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Climb Bio to present Phase 2 data on kidney disease therapies - Investing.com Nigeria
Climb Bio to Present Preliminary Phase 2 Budoprutug Data in Primary Membranous Nephropathy at ASN Kidney Week 2026 - Quiver Quantitative
Climb Bio to present Phase 2 data on kidney disease therapies - Investing.com UK
Climb Bio (NasdaqGM:CLYM) Stock Forecast & Analyst Predictions - simplywall.st
Preliminary data from a kidney disease drug study were selected for an October talk. - Stock Titan
Form 4 Climb Bio Inc For: 1 October - Investing.com India
Form 4 Climb Bio Inc For: 1 October By Investing.com - Investing.com Canada
Form 4 Climb Bio Inc For: 1 October By Investing.com - Investing.com Nigeria
Options for 70,000 shares were exercised at $1.29–$7.89 in Climb Bio (CLYM). - Stock Titan
Form 4 Climb Bio Inc For: 1 October By Investing.com - Investing.com Australia
Nuvectis Pharma (Nasdaq:NVCT)Stock Analysis - simplywall.st
About $19 million in liabilities are extinguished after a $450,000 payment to settle litigation. - stocktitan.net
Director Stephen Thomas Sells 100,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Climb Bio (CLYM) director sells 100K shares in preset plan - Stock Titan
Climb Bio (NASDAQ: CLYM) director files to sell insider stake - Stock Titan
Climb Bio presents initial Phase 1 data for CLYM116 - Traders Union
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com Nigeria
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com Canada
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com UK
H.C. Wainwright raises Climb Bio stock price target on drug data By Investing.com - Investing.com Australia
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Australia
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating - Moomoo
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Nigeria
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating - marketscreener.com
H.C. Wainwright raises Climb Bio stock price target on drug data - investing.com
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Canada
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com Canada
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com South Africa
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com India
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com UK
Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com
Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com Nigeria
Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $25 to $40 - Moomoo
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Canada
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Australia
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com India
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com Australia
Baird raises Climb Bio stock price target to $25 on trial data By Investing.com - Investing.com South Africa
BTIG raises Climb Bio stock price target to $32 on phase 1 data By Investing.com - Investing.com South Africa
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Nigeria
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com Canada
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com India
Climb Bio Inc Azioni (CLYM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Climb Bio Inc Azioni (CLYM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| STEPHEN THOMAS | Director |
Sep 15 '26 |
Proposed Sale |
14.56 |
100,000 |
1,456,000 |
0 |
| Thomas Stephen Basil | Director |
Sep 15 '26 |
Sale |
13.67 |
100,000 |
1,366,820 |
467,969 |
| AOIFE BRENNAN | Officer |
Jun 29 '26 |
Proposed Sale |
13.17 |
30,902 |
406,968 |
0 |
| Brennan Aoife | President and CEO |
Jun 29 '26 |
Sale |
13.17 |
30,902 |
406,979 |
87,731 |
| Thomas Stephen Basil | Director |
Feb 26 '26 |
Sale |
7.01 |
16,313 |
114,289 |
154,657 |
| STEPHEN THOMAS | Director |
Feb 25 '26 |
Proposed Sale |
6.36 |
50,000 |
318,000 |
0 |
| Thomas Stephen Basil | Director |
Feb 25 '26 |
Sale |
7.00 |
33,687 |
235,964 |
170,970 |
| Thomas Stephen Basil | Director |
Feb 13 '26 |
Sale |
5.81 |
10,000 |
58,141 |
204,657 |
| Thomas Stephen Basil | Director |
Feb 12 '26 |
Sale |
5.23 |
90,000 |
470,988 |
214,657 |
| STEPHEN THOMAS | Director |
Feb 12 '26 |
Proposed Sale |
5.56 |
100,000 |
556,000 |
0 |
3.40%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):